N@N

NEW YORK--([ BUSINESS WIRE ])--Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimeras Immunotherapy Program (AIP), Janssen Alzheimer Immunotherapy, and the Geoffrey Beene Gives Back Alzheimeras Initiative today introduced the Alzheimeras Challenge 2012 at the Care Innovations Summit in Washington, D.C. The Alzheimeras Challenge 2012 calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimeras disease.

"We hope meeting our Challenge may help improve the individual experiences of people living with Alzheimeras disease and their caregivers. This could be a huge step to advance the global fight against Alzheimeras and other dementias."

Specifically, the Challenge seeks the development of simple, cost-effective, consistent tools that could be easily used to assess memory, mood, thinking and activity level over time to help improve diagnosis and monitoring of people with Alzheimeras disease. Today, easy to use, reliable, objective and cost-efficient methods to track and monitor Alzheimeras disease -- which is not a normal part of aging -- remain an unmet need. The Alzheimeras Challenge 2012 supports the U.S. Department of Health and Human Services (HHS) call to harness new thinking to deliver better care and better health at lower cost and provides an entrepreneurial springboard to harness new thinking and approaches to improve Alzheimeras care.

aEach person diagnosed with Alzheimeras disease experiences its devastating impact differently,a said Michael Williams, vice president, Primary Care Business Unit, Pfizer Inc., on behalf of the Alzheimeras Immunotherapy Program. aWe hope meeting our Challenge may help improve the individual experiences of people living with Alzheimeras disease and their caregivers. This could be a huge step to advance the global fight against Alzheimeras and other dementias.a

The Alzheimeras Challenge 2012 includes awards totaling $300,000. This incorporates $25,000 to five finalists and $175,000 to one winner of the Challenge. The deadline for submission of concepts is March 16, 2012 and a complete Challenge description, official rules, including prizes, judging criteria and timelines are available on the AlzheimerasChallenge 2012 website [ www.alzheimerschallenge2012.com ].

aThe organizations presenting challenges here today are pushing the best minds in the country to create a better health care system. They represent exciting solutions to help address some of the Nationas most urgent health needs,a said CMS Acting Administrator Marilyn Tavenner.

aWe believe someone out there has the answer and shares our sense of urgency. The AlzheimerasChallenge 2012 is open to problem-solvers and we encourage anyone and everyone who thinks they have a creative solution to step up, submit an entry, and be recognized,asaid Meryl Comer, president ofThe Geoffrey Beene Foundation Alzheimeras Initiative. Chairman of the Initiative, George Vradenburg, also representing USAgainstAlzheimers on the National Alzheimeras Project Act (NAPA), adds, aWe are pleased to partner with the AIP in making thisChallengeand are grateful for the continuing leadership of HHS Secretary Sebelius in focusing a broad-based national effort to address Alzheimeras.a

Alzheimeras Challenge 2012 Overview

Following the March 16, 2012 submission deadline, five finalists will be selected and announced by April 16, 2012. Each finalist will be awarded $25,000. Concept refinement will be completed by mid June 2012 with finalist presentations to follow. The winner of the Challenge will be announced at the end of June 2012 and awarded a $175,000 prize. Judges will be drawn from experts in the Alzheimeras community and other related fields. More information available at [ www.alzheimerschallenge2012.com ].

The Need for Better Tools to Track Alzheimeras Disease

For many chronic conditions, such as diabetes and hypertension, there are simple, reliable, objective methods for tracking progression. Similar tools are generally not available for Alzheimeras disease. However, there are accurate and reliable cognitive tests to help diagnose the disease. Other challenges still remain in the diagnosis of and ongoing care for people with Alzheimeras disease.

It is believed that as many as 50 percent of people living with dementia in high income countries such as the United States have not received a formal diagnosis. Once diagnosed, patients, their caregivers and healthcare providers need a better way to track and monitor the patientas condition over time.

Alzheimer's Immunotherapy Program

The Alzheimer's Immunotherapy Program of Janssen Alzheimer Immunotherapy and Pfizer Inc. is an equal collaboration committed to researching and developing selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimeras disease.

The Alzheimer's Immunotherapy Program believes that it is possible to reduce the burden of disease through early intervention in the illness. It is dedicated to delivering comprehensive and integrated solutions that help address the needs of people impacted by Alzheimeras disease.

Its research focuses on the beta amyloid hypothesis. Scientific evidence supports the idea that preventing the accumulation and/or promoting the removal of beta-amyloid may have the potential to slow the progression of Alzheimeras disease and help preserve function in people with the disease. This theory is being tested in clinical trials.

Pfizer Inc: Working together for a healthier world

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the worldas best-known consumer products.Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.Consistent with our responsibility as the worldas leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.For more than 150 years, Pfizer has worked to make a difference for all who rely on us.To learn more about our commitments, please visit us at [ www.pfizer.com ].

The Geoffrey Beene Gives BackAlzheimeras Initiative

The Geoffrey Beene Gives Back Alzheimeras Initiative (GBGBAI) is a major charitable beneficiary of the Geoffrey Beene Foundation. Its missionis"getting ahead of the future" with early diagnostics, genetics, biomarker research and spirited public awareness campaigns. The 2012 Alzheimeras Challengeis the first in a series of GBGBAI-supported, award based competitions for innovative solutions to challengestoAlzheimer's prevention research. A marquee sponsor of the 2010 award-winning HBO series, "The Alzheimer's Project," GBGBAI also launched a national aRock Stars of Sciencea (Rock S.O.S.) campaign to salute researchers and excite the next generation to careers in science. One hundred percent of net profits from Geoffrey Beene, LLC are donated to philanthropic causes that support innovative research on a host of medical, educational and societal issues. Through 2011, Geoffrey Beene, LLC has provided $150 million in value funding. For more information, visit[ www.geoffreybeene.com ] or[ www.rockstarsofscience.org ].